Key result
Once-daily edoxaban shows effective stroke prevention with zero major bleeds in a high-risk NVAF series.
Why the study?
To share early clinical experiences and discuss the evidence-based use of once-daily edoxaban in NVAF patients in Southeast Asia.
Case Report (n=7)
Yes
This case series illustrates the real-world safety and effectiveness of edoxaban for stroke prevention in high-risk Southeast Asian patients with non-valvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support edoxaban in high-risk Southeast Asian AF patients; hypothesis-generating and leaves open need for larger trials.
Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism. The clinical benefit of edoxaban for stroke prevention in Asian patients with NVAF has been demonstrated in clinical and real-world studies. We share early clinical experiences with once-daily edoxaban and discuss its evidence-based use in patients with NVAF in Southeast Asia through several cases of patients at high risk, including frail patients, elderly patients with multiple comorbidities and patients with increased bleeding risk. These cases demonstrate the effectiveness and safety of once-daily edoxaban in patients with NVAF in Southeast Asia.
No takes yet. Share an insight, caveat, or question.
Diaz et al. (2023) conducted a case report in Non-valvular atrial fibrillation (n=7). Edoxaban was evaluated on Stroke prevention and bleeding events. In a case series of seven high-risk patients with non-valvular atrial fibrillation in Southeast Asia, once-daily edoxaban was effective for stroke prevention with no reported major bleeding events.
Synapse has enriched 10 related papers. Consider them for comparative context: